Arm A :No Intervention/control: Standard treatment
Antibiotics for secondary bacterial infection as per institutional guidelines
Supplemental oxygen (to keep saturations between 90% to 96%)
Intravenous hydration (to maintain euvolumia)
Thrombo-prophylaxis as per local guidelines
Paracetamol (oral or I/V 1gram QDS as required or regular)
To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)

Arm B: Experimental Arm received oral co-trimoxazole + standard therapy
The following treatments are recommended as standard therapy:
Antibiotics for secondary bacterial infection as per institutional guidelines
Supplemental oxygen (to keep saturations between 90% to 96%)
Intravenous hydration (to maintain euvolumia)
Thrombo-prophylaxis as per local guidelines
Paracetamol (oral or I/V 1gram QDS as required or regular)
To consider steroids if indicated (i.e. acute exacerbation of COPD or acute severe asthma)

Covid19

Severe COVID-19 Patients

oral co-trimoxazole

Bangabandhu Sheikh Mujib Medical University

Role of Co-trimoxazole in Severe COVID-19 Patients

ratio of Saturation of oxygen in % and Fraction of inspired oxygen

Requirement of ventilator support in hours

% of patients developed early reaction like fever, rash, abdominal pain, urticaria, vomiting, wheezing, chest tightness

Data will be shared with the journal authority and make public as part of the publication

Prof. Dr. Shohael Mahmud Arafat

Chairman and professor of internal medicine

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Anwar Khan Mordern Medical College and Hospital, Dhaka

Mugda Medical College and Hospital, Dhaka

Arm A :control group will receive standard treatment, Arm B: experimental group will receive standard care and oral co-triamoxazole

The clinical charts of NCWS patients, diagnosed by DBPC gluten/wheat challenge, between January 2001 and December 2019, attending the Department of Internal Medicine at the University Hospital of Palermo, the Department of Internal Medicine of the Hospital of Sciacca, and the Department of Medical and Surgical Sciences of the University of Bologna, will be reviewed retrospectively. The investigators prospectively will also survey patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS by DBPC gluten/wheat challenge. The patients will be recruited between January 2019 and January 2022 at the same centers, and at the Internal Medicine Division of the "Cervello-Villa Sofia" Hospital of Palermo, Palermo.

To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of a control group of CD patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of CD patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.

To compare the presence and characteristics of anemia in NCWS patients, the clinical charts of another control group of IBS patients had been randomly chosen by a computer-generated method from patients diagnosed in the same centers, during the same period (2001-2019), and age- and sex-matched with the NCWS patients. The investigators prospectively will also survey a control group of IBS patients randomly chosen by a computer-generated method from subjects diagnosed in the same centers, during the same period (2019-2022), and age- and sex-matched with the NCWS patients.

Non-celiac Gluten Sensitivity

Anemia

Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.

Evaluation of anemia

Department of Internal Medicine, Giovanni Paolo II Hospital of Sciacca

Internal Medicine Division of the "Cervello-Villa Sofia" Hospital

Department of Internal Medicine, University Hospital of Palermo

Anemia in Non-celiac Wheat Sensitivity

Clinical Characteristics and Pathogenic Mechanisms of Anemia in Non-celiac Wheat Sensitivity Compared to Celiac Disease and Irritable Bowel Syndrome

red blood cells (adults references ranges, RR, 4.5-5.9 million cells/mcL, men, 4.1-5.1 million cells/mcL, women), hemoglobin (RR 13-17 g/dL, men, 12-15 g/dL, women), hematocrit (RR 40%-52%, men, 36%-47%, women), mean corpuscular volume (RR 80-100 fL), mean corpuscular hemoglobin (RR 0.4-0.5 fmol/cell), mean corpuscular hemoglobin concentration (RR 30-35 g/dL), red cell distribution width (RR 11.5%-14.5%)

reticulocytes count (RR 0.5%-1.5%), total serum iron (RR 65-180 µg/dL, men, 30-170 µg/dL, women), ferritin (RR 12-300 ng/mL, men, 12-150 ng/mL, women), transferrin (200-350 mg/dL), total iron-binding capacity (RR 45-85 µmol/L), vitamin B12 (RR 130-700 ng/L), folic acid (RR 7-36 nmol/L), thyroid-stimulating hormone (TSH, RR 2-10 μU/mL), anti-nuclear antibodies (ANA), anti-intrinsic factor (IFA) and/or parietal cell (APCA) antibodies

Pasquale Mansueto

Principal Investigator

University of Palermo

To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS

12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.

Intrathecal methotrexate

Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study

Disability will be measured every visit by the Multiple Sclerosis Functional Composite (MSFC)

adverse events will be followed until resolution. Serious adverse events will be reported to the IRB within 24 hours of noticed.

(Composite measure) We will measure new gd+ enhancing lesions, number of lesions, brain and upper spinal cord atrophy and cortical thickness and compare these measure between the time before and after treatment along. Overall each participant will undergo 5 scans , the first before treatment installation and then before each treatment . one scan will be done 3 month after the last treatment

(Composite measure) Cerebrospinal fluid (CSF) sample will be obtained and analyze for parameters including cell count and differential, protein and glucose concentration, oligoclonal bands, IgG concentration, cellular analysis by flow cytometry for CD3+, CD20+, CD14+ cell subsets, and measurement of several soluble mediators such as: CXCL13, CD23, light chains, TNFa, IFNg, IL-17, IL-2, IL-10, BDNF and Neurofilaments will be studied by ELISA

michal roll

Director R&D Division

Tel-Aviv Sourasky Medical Center

Resectable, Non-functioning Pituitary Adenoma

Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.

folate/sakit kepala

Role of Co-trimoxazole in Severe COVID-19 Patients

Anemia in Non-celiac Wheat Sensitivity

Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Database tanaman obat terlengkap yang didukung oleh sains